<https://helda.helsinki.fi>

HLA-G polymorphism impacts the outcome of oral HPV infections in women

Jaakola, Anna

2021-05-04

Jaakola , A , Roger , M , Faucher , M-C , Syrjanen , K , Grenman , S , Syrjänen , S & Louvanto , K 2021 , ' HLA-G polymorphism impacts the outcome of oral HPV infections in women ' , BMC Infectious Diseases , vol. 21 , no. 1 , 419 . <https://doi.org/10.1186/s12879-021-06079-7>

<http://hdl.handle.net/10138/331182>

<https://doi.org/10.1186/s12879-021-06079-7>

cc_by

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

RESEARCH ARTICLE

Open Access

HLA-G polymorphism impacts the outcome of oral HPV infections in women

Anna Jaakola^{1,2*} , Michel Roger^{3,4}, Marie-Claude Faucher³, Kari Syrjänen⁵, Seija Grénman¹, Stina Syrjänen^{6,7} and Karolina Louvanto^{6,8}

Abstract

Background: Human leukocyte antigen (HLA)-G may have an important role in the natural history of human papillomavirus (HPV) infection. Our aim was to evaluate the role of HLA-G in the outcome of genital and oral HPV infections in women.

Methods: Analyses included 306 women from the Finnish Family HPV-study and were followed-up for six years. Genital and oral samples were tested for 24 different HPV types with multiplex HPV genotyping. HLA-G alleles were determined through direct DNA-sequencing. Unconditional logistic regression was used to determine the associations between HLA-G genotypes and HPV infection outcomes.

Results: Ten HLA-G alleles were identified. Most common HLA-G genotypes were the wild type G*01:01:01/01:01:01 (31.3%) followed by G*01:01:01/01:01:02 (26.8%). G*01:01:01/01:01:01 genotype was associated with increased risk of oral HPV infections by any HPV type or single-type with OR = 1.86 (95% CI 1.14–3.04, $P = 0.01$) and 2.22 (95% CI 1.14–3.71, $P = 0.02$), respectively. G*04:01+ allele and the G*01:01:01/01:04:01 genotype both protected from any and single oral HPV infections; OR = 0.46 (95% CI 0.23–0.89, $P = 0.02$) and 0.53 (95% CI 0.23–0.97, $P = 0.03$), respectively. G*01:01:02/01:04:01 genotype increased significantly the risk of infertility and its treatments, with respective OR = 5.06 (95% CI 1.22–21.02, $P = 0.03$) and OR = 9.07 (95% CI 1.22–39.50, $P = 0.03$). Both HLA-G alleles and genotypes showed several significant associations with the outcomes of oral HPV infections, but none of them had any impact on the outcomes of genital HPV infections in these women.

Conclusions: The host HLA-G genotypes appear to impact the outcomes of oral HPV infections in women but have little if any effect on genital HPV status or infection outcomes.

Keywords: Human papilloma virus, HPV, HLA-G, Genotype, Oral, Infection

Background

Human Papillomavirus (HPV) infections are highly common, and it is estimated that 80% of sexually active women contract a HPV-infection during their lifetime [1–3]. Persistent genital infection with high-risk (HR) HPV is shown to be involved in nearly all cervical cancers and its precursors [4–7]. Increasing evidence also

implicates that HPV infections play a significant role in the etiology of head and neck carcinomas, oropharyngeal cancer in particular [8, 9]. Globally, HPV infections are currently associated up to 4,5% of all new cancer cases and among women 8,6% new cancer cases are HPV induced [5, 7].

Only a small percentage of HPV infections progress to cervical cancer (CC). Impaired reactivity of the cell-mediated immunity (CMI) and the human leukocyte antigen (HLA) system to viral antigens seem to increase the risk of CC [10, 11]. The vast majority of the previous

* Correspondence: ajjaak@utu.fi

¹Turku University Hospital, University of Turku, Turku, Finland

²Department of Obstetrics and Gynecology, Kymenlaakso Central Hospital, Kotkantie 41, 48210 Kotka, Finland

Full list of author information is available at the end of the article

© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

studies have focused on the association between HLA class II alleles and cervical carcinoma [11–15], but data are emerging to implicate an association between HLA-G polymorphisms and the natural history of cervical HPV infections (prevalence and persistence) as well as in cervical and oral carcinomas [11–15]. Human leukocyte antigen (HLA)-G is a non-classical HLA class Ib molecule, first identified to be present in placental cells of fetal origin and playing a role in immune tolerance during pregnancy [16–18]. However, HLA-G can be expressed de novo at high levels in several pathological conditions, including some tumors as well as during microbial or viral infections, leading to the impairment of the immune response against tumor cells or infectious pathogens, respectively [11, 19]. HLA-G has been found to play an important role in several aspects of the female reproductive health [12, 20–24].

In the present study, our aim was to evaluate the potential impact of HLA-G polymorphism in the outcomes of genital and oral HPV infections among women as well as the HLA-G role in different characteristics of the female reproductive health.

Methods

Finnish family HPV-study

The present study is part of the Finnish Family HPV (FFHPV) cohort study, which was initiated in 1998 to investigate the dynamics of HPV transmission between the family members [25, 26]. At baseline, 329 pregnant mothers, 171 fathers and 331 their newborn babies were recruited. The present study focus only on women followed at 3rd trimester (>36 gestational weeks), 2-, 6-, 12-, 24-, 36- and 72-months' visits (between the years 1998 to 2006) as described earlier [25]. All the families are of Caucasian origin (native Finnish population). At the baseline visit, all women were pregnant (>36 gestational weeks), with the mean age of 25.6 years (SD $\pm$ 0.2), range 18–46 years. Detailed data were collected by structured questionnaire at baseline, complemented with the information about the delivery as well as the child's anthropometrics. The Research Ethics Committee of Turku University Hospital (#3/1998 and #2/2006) has approved the study protocol and its amendments. All the participants gave their written consent for the cohort study.

Samples

Oral and genital scrapings from all women were collected for HPV-testing with a cytobrush (MedScand, Malmö, Sweden) at baseline and during the follow-up visits at 2, 6, 12, 24, 36 and 72 months [25]. HPV was detected with PCR, using My09/My11 and GP05+/GP06+ – primers, as previously described in detail [27]. Samples were all tested with Luminex-based Multimerix

kit, which detects 24 low-risk (LR)- and high-risk (HR)-HPV genotypes (LR-HPV: 6, 11, 42, 43, 44 and HR-HPV: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82. Genomic DNA for HLA-G typing was isolated from frozen blood cells using MagNA Pure 96 System (Roche). HLA-G alleles were determined by direct DNA-sequencing of the nucleotide regions encompassing the HLA-G exons 2–4 (1718 bp) as previously described [12].

Statistical analysis

This study includes 306 women of the FFHPV-Study. Stata 15.0 (Stata Corp., College Station, TX) was used for all statistical analyses, performed two-sided and declared significant at the P -value < 0.05 level. Women with no HLA-G genotyping result available ($n = 23/329$) were excluded from the analyses. Woman was classified as HPV positive when any of the samples taken during the 72 months follow-up was HPV positive (any type as single or multiple infection. Single infection defined as always only one HPV type present at the follow-up visits and multiple HPV infection as two or more HPV types presented simultaneously during the follow up visits. In statistical analysis, we only considered HLA alleles and genotypes that were present in at least in 3% of the study group. Low resolution groups were generated for the following alleles Group 01:01: *010101, *010102, *010103, *010114 and Group 04:01: *01040 and *010404.

Unconditional logistic regression analysis was used to determine the associations between HLA-G alleles or genotypes and the genital and oral HPV-infection outcomes as well as their role as risk factors of several reproductive health endpoints. An incident HPV-infection was recorded when a baseline HPV-negative woman tested HPV-positive at any of the follow-up visits. HPV clearance denotes all cases where a previously HPV-positive women tested HPV-negative at any follow-up visits and remained HPV-negative until the end of the follow-up. Persistent HPV infection was defined when HPV positivity was recorded in two or more consecutive visits during the follow-up.

Results

Ten different HLA-G alleles and 24 different genotype combinations were identified among the women of the FFHPV study. HLA-G alleles and genotypes with > 3% prevalence are shown in Fig. 1. The most common HLA-G allele was the wild-type *01:01:01 of which 32% ($n = 98$) of the women being homozygous, 52% ($n = 159$) heterozygous and only 16% ($n = 49$) women missing this allele. Of the HLA-G genotypes, *01:01:01/01:01:01 (31.3%) was the most prevalent, followed by G*01:01:01/01:01:02 (26.8%).

HLA-G alleles and genotypes as related to genital and oral HPV-prevalence (single and multiple-type) are depicted in Table 1. No significant associations were observed between HLA-G alleles/genotypes and genital HPV infections. As to oral HPV infections, allele G*01:01:03 and genotype G*01:01:01/01:01:03 were associated with increased risk of multiple-type oral HPV infections during the follow up, OR = 3.32 (95% CI 1.18–9.34, $P = 0.02$) and OR = 4.44 (95% CI 1.39–14.20, $P = 0.01$), respectively. G*01:01:01/01:04:01 genotype and the G*01:04+ group both protected from any and single-type oral HPV infections; OR = 0.46 (95% CI 0.23–0.89, $P = 0.02$) and OR = 0.53 (95% CI 0.30–0.94, $P = 0.03$), respectively. G*01:01:01/01:01:01 genotype seemed to predispose the women to any HPV type or single-type infection with OR = 1.86 (95% CI 1.14–3.04, $P = 0.01$) and OR = 2.22 (95% CI 1.14–3.71, $P = 0.02$), respectively.

HLA-G alleles, groups and genotypes as related to genital and oral HPV infection outcomes (always negative, incidence, clearance and persistence) are shown in Table 2. No significant association was detected between the genital HPV-infection outcomes and HLA-G alleles or genotypes. As to oral HPV infections, allele G*01:01:02 was associated with decreased clearance of oral HPV infection OR = 0.50 (95% CI 0.29–0.79, $P = 0.03$) and the genotype G*01:01:02/01:04:01 increased the risk of oral persistence, with OR = 4.01 (95% CI 1.19–13.53, $P = 0.03$). HLA Group G04:01+ decreased the risk of incident oral HPV by 2-fold; OR = 0.51 (95% CI 0.27–0.98, $P = 0.03$) and increased the probability of women remaining HPV-negative throughout the follow-up; OR = 1.87 (95% CI 1.06–3.30). Similar association with

always HPV-negative status was also found for genotype G*01:01:02/01:04:01, with OR = 2.18 (95% CI 1.12–4.26, $P = 0.02$). Genotype G*01:01:01/01:01:01 was related to increased clearance of any oral HPV infection but also decreased the probability of always HPV-negative status with OR = 1.18 (95% CI 1–28.371, $P = 0.01$) and OR = 0.54 (95% CI 0.33–0.88, $P = 0.02$), respectively (Table 2).

We also investigated the associations between HLA-G alleles and genotypes with reproductive risk factors of HPV infection recorded in these women at baseline and during the follow-up (Table 3 and 4). At the HLA-G allele level only allele G*01:01:02 showed associated with increased risk of having atopic tendency, OR = 1.9 (95% CI 1.00–3.73, $P = 0.05$) while allele *01:06 increased the risk having an induced labour, OR = 6.48 (95% CI 1.28–32.77, $P = 0.02$) (Table 3). In HLA-G allele groups, G*01:01- group was associated with decreased risk of having an early labor (< 37 week), OR = 0.07 (95%CI 0.01–0.72, $P = 0.03$). This trend was also seen in the high resolution wild type alleles, but it did not, $P = 0$. reach statistical significance. At the genotype level (Table 4), HLA-G*01:01:02/01:04:01 was associated with an increased infertility and the recorded treatments, with respective OR = 5.06 (95%CI 1.22–21.02, $P = 0.03$) and OR = 9.07 (95% CI 1.22–39.50, $P = 0.03$). Genotype G*01:01:02/01:04:01 was shown to decrease the likelihood of skin wart history during follow-up, OR = 0.18 (95%CI 0.04–0.87, $p = 0.03$). Self-reported oral warts were associated with genotypes G*01:01:01/01:01:02 and G*01:01:01/01:01:03, with OR = 4.85 (95% CI 1.13–20.85, $P = 0.03$) and OR = 6.00 (95% CI 1.11–32.46, $P = 0.04$), respectively. In addition, HLA-G*01:01:01/01:01:03 genotype showed a

Table 1 HLA-G alleles, low-resolution groups and genotypes, as related to genital and oral HPV status¹ of the women

HLA-G	Genital			Oral		
	Any HPV (n = 250)	Single (n = 119)	Multiple (2+) (n = 131)	Any HPV (n = 154)	Single (n = 120)	Multiple (2+) (n = 34)
Alleles						
*01:01:01	1.01 (0.46–2.21)	0.84 (0.36–1.98)	1.20 (0.50–2.87)	0.88 (0.48–1.62)	1.01 (0.52–1.97)	0.58 (0.23–1.44)
*01:01:02	0.94 (0.52–1.70)	0.90 (0.47–1.73)	0.97 (0.52–1.84)	0.83 (0.53–1.31)	0.83 (0.51–1.35)	0.85 (0.40–1.83)
*01:01:03	0.88 (0.34–2.28)	0.76 (0.26–2.22)	1.00 (0.36–2.74)	1.80 (0.83–3.93)	1.42 (0.61–3.35)	3.32 (1.18–9.34)
*01:03:01	0.89 (0.18–4.32)	0.94 (0.17–5.29)	0.85 (0.15–4.78)	0.24 (0.05–1.13)	0.15 (0.02–1.23)	0.55 (0.07–4.51)
*01:04:01	1.02 (0.49–2.12)	1.03 (0.47–2.29)	1.01 (0.46–2.22)	0.57 (0.32–1.02)	0.55 (0.29–1.02)	0.67 (0.26–1.73)
*01:06	2.29 (0.29–18.28)	3.44 (0.41–28.64)	1.29 (0.13–12.67)	1.76 (0.51–6.15)	1.28 (0.31–5.21)	3.58 (0.76–16.81)
Groups ²						
G01:01	1.12 (0.12–10.20)	1.06 (0.09–11.98)	1.17 (0.10–13.20)	0.67 (0.11–4.07)	0.79 (0.11–5.67)	0.44 (0.04–5.00)
G04:01	1.07 (0.52–2.22)	1.09 (0.49–2.40)	1.06 (0.49–2.32)	0.53 (0.30–0.94)	0.51 (0.28–0.95)	0.62 (0.24–1.61)
Genotypes						
010101:010101	0.80 (0.44–1.47)	0.84 (0.43–1.65)	0.76 (0.39–1.48)	1.86 (1.14–3.04)	2.22 (1.32–3.71)	0.92 (0.39–2.21)
010101:010102	0.82 (0.44–1.55)	0.71 (0.35–1.44)	0.94 (0.47–1.86)	0.73 (0.44–1.21)	0.80 (0.47–1.37)	0.49 (0.19–1.27)
010101:010103	1.97 (0.44–8.78)	1.95 (0.40–9.48)	1.99 (0.42–9.53)	1.75 (0.67–4.57)	1.09 (0.36–3.33)	4.44 (1.39–14.20)
010101:010401	1.01 (0.44–2.31)	0.93 (0.37–1.33)	1.08 (0.45–2.62)	0.46 (0.23–0.89)	0.47 (0.23–0.97)	0.41 (0.12–1.44)
010102:010102	2.05 (0.25–16.55)	2.92 (0.43–24.86)	1.29 (0.13–12.67)	1.50 (0.41–5.42)	1.28 (0.31–5.21)	2.31 (0.41–13.17)
010102:010401	2.29 (0.29–18.28)	2.92 (0.34–24.86)	1.73 (0.19–15.85)	1.19 (0.36–3.99)	1.01 (0.27–3.86)	1.84 (0.34–9.90)

¹HPV positivity taken as positive for any HPV type during the 72 months follow-up (part of single or multiple infection), Single infection: always only one HPV type present at the follow-up visits and multiple: two or more HPV types presented during the follow up visits. ²Groups as low resolution for the following alleles G01:01: *010101, *010102, *010103, *010114 and G04:01: *01040 and *010404. Only those HLA-G alleles and genotypes that where > 3% prevalent among the women where included to the analyses. The significant associations are bolded

significant association with an abnormal placenta, OR = 5.51 (95% CI 1.03–29.37, $P = 0.05$).

Discussion

In the present study, we identified ten different HLA-G alleles and 24 different genotype combinations among the 306 women of the FFHPV-Study. We found an association with certain HLA-G alleles and genotypes with the outcomes of oral HPV-infections, but interesting enough no such associations with the outcomes of genital HPV-infections. Additionally, certain HLA-G alleles and genotypes seemed to be linked with some characteristics of the women's reproductive health.

So far there are only a few studies available investigating the impact of HLA-G polymorphism in the natural history of HPV-infections. Most of these investigations are evaluating the association between HLA-G and HPV-induced cervical premalignant and malignant lesions [12, 13, 21–24]. The data on HLA-G polymorphism in oral HPV-infections are, to our knowledge, lacking. So far, these studies have evaluated malignant lesions of the oropharynx, where HLA-G polymorphism have been studied, but only using immunohistochemistry in the biopsy samples with mono-/or polyclonal antibodies for HLA-G or assessing the polymorphic sites at 5'URR (upstream regulatory region) and 3'UTR

(untranslated region) by polyacrylamide gel electrophoresis (PAGE) [22–24]. In our study none of the women developed any premalignant or malignant oral lesions during the six-year follow-up. Oral mucosa was carefully examined at the last visit [28].

Our results revealed that homozygous wildtype genotype G*01:01:01/01:01:01 showed to increase both the clearance of any oral HPV infection (OR = 1.18) (Table 2) and having any oral HPV-infections during the follow-up (OR = 1.86) (Table 1). However, this wild-type genotype did not impact on the HPV persistence that would be mandatory for the progression of an asymptomatic infection to a HPV induced premalignant lesion (i.e. oral potentially malignant lesion). A similar protective effect for oral HPV infection was seen with G*04:01+ (OR 1.87) as with genotype G*01:01:01/01:04:01 (OR 2.18). There are no previous studies on the oral mucosa with the HLA-G wildtype, but a few regarding the genital mucosa [12, 13, 23]. Of these studies only Metcalfe and coworkers showed that allele G*01:01:01 (OR = 2.23) and heterozygous genotype with G*01:01:01 (OR = 2.14) were increasing both the risks of genital LR-HPV infection and genital multiple-type infections versus single-type infections [23]. However, these infections might not progress toward malignancy as Ferguson et al. reported that heterozygotic form of the HLA-G*01:01:01 allele

Table 2 HLA-G alleles, low-resolution groups and genotypes as related to outcomes of the genital and oral HPV infections during the six-year follow-up

HLA-G	Genital HPV infection outcomes ¹				Oral HPV infection outcomes ¹			
	Always negative (n = 106)	Incidence (n = 200)	Clearance (n = 57)	Persistence (n = 143)	Always negative (n = 205)	Incidence (n = 101)	Clearance (n = 27)	Persistence (n = 74)
Alleles	OR (95% CI)				OR (95% CI)			
*01:01:01	0.99 (0.45–2.19)	0.72 (0.37–1.40)	1.14 (0.61–2.12)	0.81 (0.44–1.50)	1.14 (0.62–2.10)	1.14 (0.59–2.21)	1.92 (0.86–4.29)	0.68 (0.34–1.32)
*01:01:02	1.06 (0.59–1.92)	1.08 (0.67–1.75)	0.88 (0.55–1.40)	1.06 (0.67–1.67)	1.20 (0.76–1.90)	0.87 (0.53–1.42)	0.50 (0.29–0.79)	0.96 (0.56–1.65)
*01:01:03	1.13 (0.44–2.91)	1.26 (0.56–2.87)	1.18 (0.54–2.64)	1.34 (0.63–2.85)	0.55 (0.25–1.21)	1.90 (0.89–4.07)	1.07 (0.46–2.51)	1.16 (0.49–2.72)
*01:03:01	1.12 (0.23–5.42)	0.79 (0.22–2.86)	1.14 (0.32–4.13)	2.75 (0.70–10.82)	4.22 (0.88–20.22)	0.50 (0.10–2.39)	NC	0.34 (0.04–2.72)
*01:04:01	0.98 (0.47–2.03)	0.78 (0.44–1.38)	1.08 (0.61–1.91)	0.81 (0.46–1.43)	1.74 (0.98–3.09)	0.54 (0.28–1.04)	0.66 (0.33–1.33)	0.92 (0.47–1.78)
*01:06	0.44 (0.05–3.48)	2.45 (0.52–11.55)	1.34 (0.38–4.68)	0.64 (0.18–2.24)	0.57 (0.16–1.98)	1.17 (0.33–4.08)	1.10 (0.28–4.25)	1.84 (0.52–6.46)
Groups ²								
G01:01	0.89 (0.10–8.16)	1.26 (0.21–7.68)	0.32 (0.04–2.94)	0.58 (0.09–3.52)	1.49 (0.25–9.05)	0.74 (0.12–4.47)	1.38 (0.15–12.49)	0.47 (0.77–2.88)
G04:01	0.93 (0.45–1.92)	8.83 (0.47–1.47)	1.06 (0.60–1.87)	0.89 (0.51–1.55)	1.87 (1.06–3.30)	0.51 (0.27–0.98)	0.63 (0.32–1.26)	0.87 (0.45–1.69)
Genotypes								
010101:010101	1.25 (0.68–2.29)	1.19 (0.71–1.99)	1.01 (0.61–1.65)	0.87 (0.54–1.41)	0.54 (0.33–0.88)	1.49 (0.90–2.47)	1.18 (1–28–3.71)	1.44 (0.83–2.49)
010101:010102	1.22 (0.64–2.29)	0.79 (0.47–1.33)	1.09 (0.66–1.84)	0.89 (0.54–1.47)	1.37 (0.83–2.28)	0.90 (0.52–1.55)	0.62 (0.33–1.51)	0.75 (0.41–1.38)
010101:010103	0.51 (0.11–2.26)	2.99 (0.85–10.49)	1.09 (0.40–2.94)	1.61 (0.63–4.13)	0.57 (0.22–1.49)	1.91 (0.75–4.85)	1.05 (0.36–3.01)	1.49 (0.54–4.06)
010101:010401	0.99 (0.43–2.27)	0.59 (0.31–1.12)	0.95 (0.50–1.82)	0.68 (0.35–1.31)	2.18 (1.12–4.26)	0.64 (0.31–1.32)	0.97 (0.46–2.03)	0.45 (0.18–1.11)
010102:010102	0.49 (0.06–3.92)	1.25 (0.32–4.92)	0.60 (0.16–2.27)	1.14 (0.32–4.04)	0.67 (0.18–2.41)	0.87 (0.22–3.42)	1.26 (0.32–5.01)	1.36 (0.34–5.39)
010102:010401	0.44 (0.05–3.48)	5.53 (0.70–43.77)	0.91 (0.27–3.04)	1.38 (0.41–4.63)	0.84 (0.25–2.81)	0.20 (0.02–1.54)	NC	4.01 (1.19–13.53)

¹HPV outcomes definitions: incidence: baseline negative and acquired a HPV infection during follow-up, clearance: HPV positive and cleared the HPV (staying HPV negative to the end of the follow-up); persistence: recoded two or more consequence visit as HPV positive during the follow-up. ²Groups as low resolution for the following alleles G01:01: *010101, *010102, *010103, *010114 and G04:01: *01040 and *010404. Only those HLA-G alleles and genotypes that where > 3% prevalent among the women where included to the analyses. NC: Not Computable. The significant associations are bolded

conferred significant protection against cervical cancer [13]. In line with our results on the protective effect of allele G*01:04:01 for oral HPV infection, Metcalfe and coworkers also reported that homozygous HLA-G*01:04:01 genotype was related to a significantly decreased risk of genital HPV infection [23].

The allele G*01:01:02 showed to reduce the probability of clearance of oral HPV-infection (OR = 0.50) and its combined genotype G*01:01:02/01:04:01 to increase oral HPV persistence (OR = 4.01). Protective effect against multiple-type infections was also noted with genotype G*01:01:01/01:01:02 (OR = 0.49) but not with the allele G*01:01:02. Our previous findings showed HLA-G*01:01:02/01:01:02 genotype concordance, between the

mother and her child, to increase the risk of oral infection of the child by any HPV genotype and/or HR-HPV genotypes (OR 2.45) [29]. Ferguson et al. found significant associations between persistent genital HPV-16 and LR-HPV- infection with allele G*01:01:02, G*01:01:03, G*01:01:05, G*01:01:08 and G*01:03 (OR's 1.90, 2.07, 2.52, 2.17, 2.99, respectively) [12]. Later, they also reported that the homozygous G*01:01:02 genotype increased the risk of developing invasive cervical squamous cell carcinoma (OR = 3.52) [13]. Contradictory to the later, Metcalfe et al. observed that allele G*01:01:02 was significantly associated with decreased risk of any genital HPV infection (OR = 0.64) and had a protective effect against multiple type infections (OR = 0.45) [23].

Table 3 Association between HLA-G alleles as their low-resolution groups and risk factors for HPV infection recorded by the baseline questionnaire

Risk factors	HLA-G alleles OR (95%CI)						HLA-G groups OR (95%CI)	
	*01:01:01	*01:01:02	*01:01:03	*01:03:01	*01:04:01	*01:06	G01:01	G04:01
Miscarriages (≥ 1) ($n = 39$)	0.56 (0.25–1.29)	1.67 (0.83–3.35)	1.51 (0.53–4.28)	2.87 (0.71–11.65)	0.59 (0.22–1.60)	0.63 (0.08–5.03)	0.62 (0.07–5.74)	0.56 (0.21–1.52)
Infertility ($n = 24$)	0.44 (0.17–1.13)	2.28 (0.97–5.34)	0.38 (0.05–2.95)	1.19 (0.14–9.80)	0.78 (0.26–2.38)	NC	NC	0.74 (0.24–2.27)
Infertility treatments ($n = 15$)	0.37 (0.12–1.15)	2.34 (0.81–6.77)	0.65 (0.08–5.11)	NC	2.11 (0.69–6.45)	NC	0.22 (0.02–2.08)	2.01 (0.66–6.13)
Sexually transmitted diseases (HSV, Chlamydia) ($n = 63$)	1.12 (0.51–2.47)	0.62 (0.34–1.13)	1.00 (0.39–2.58)	0.44 (0.54–3.52)	0.75 (0.35–1.57)	0.89 (0.19–4.22)	0.37 (0.06–2.24)	0.82 (0.40–1.68)
Self reported warts								
Genital ($n = 80$)	0.92 (0.45–1.87)	1.08 (0.63–1.84)	0.67 (0.26–1.72)	1.10 (0.28–4.35)	1.85 (0.99–3.46)	0.56 (0.12–2.63)	0.39 (0.05–2.79)	1.91 (1.03–3.53)
Oral ($n = 8$)	1.35 (0.16–11.25)	4.82 (0.96–24.36)	3.21 (0.62–16.77)	4.07 (0.45–36.75)	NC	NC	NC	NC
Skin ($n = 166$)	1.35 (0.73–2.50)	0.90 (0.57–1.42)	1.86 (0.84–4.12)	0.57 (0.16–2.08)	0.59 (0.33–1.03)	4.12 (0.88–19.39)	0.76 (0.12–4.59)	0.64 (0.37–1.12)
Allergies ($n = 126$)	0.98 (0.51–1.87)	0.94 (0.58–1.52)	0.74 (0.33–1.70)	0.29 (0.06–1.41)	1.35 (0.75–2.43)	2.21 (0.63–7.73)	1.23 (0.20–7.48)	1.35 (0.75–2.42)
Atopia ($n = 43$)	0.51 (0.23–1.11)	1.9 (1.00–3.73)	1.23 (0.44–3.45)	0.58 (0.07–4.69)	0.93 (0.40–2.14)	1.19 (0.25–5.69)	NC	1.23 (0.57–2.69)
Vulvovaginitis ($n = 48$)	0.56 (0.11–2.87)	0.94 (0.22–4.02)	NC	4.10 (0.45–36.89)	NC	NC	NC	NC
Menarche								
Late (>14 years) ($n = 21$)	1.12 (0.31–3.99)	0.81 (0.31–2.10)	1.69 (0.46–6.20)	1.55 (0.18–13.02)	0.97 (0.31–3.01)	NC	NC	1.25 (0.44–3.62)
Early (<11 years) ($n = 7$)	1.18 (0.14–10.04)	0.60 (0.11–3.17)	NC	NC	1.57 (0.30–8.32)	4.1 (0.45–37.35)	NC	1.50 (0.28–7.93)
Start of labour								
Own contractions ($n = 145$)	1.33 (0.69–2.59)	0.83 (0.51–1.36)	0.52 (0.23–1.19)	1.19 (0.31–4.54)	1.07 (0.59–1.95)	2.93 (0.58–14.79)	0.35 (0.04–3.37)	1.02 (0.57–1.85)
Rupture of the membranes ($n = 52$)	1.15 (0.48–2.76)	1.22 (0.66–2.29)	0.33 (0.75–1.43)	0.55 (0.07–4.48)	0.59 (0.25–1.40)	NC	0.67 (0.07–6.58)	0.57 (0.24–1.36)
Induction ($n = 52$)	1.28 (0.62–2.63)	0.70 (0.42–1.19)	0.84 (0.35–2.01)	1.66 (0.43–6.33)	1.47 (0.80–2.72)	6.48 (1.28–32.77)	0.49 (0.07–3.51)	1.42 (0.77–2.62)
Labour weeks								
Early (<37 weeks) ($n = 8$)	0.95 (0.11–8.33)	0.75 (0.14–4.16)	NC	NC	0.8 (0.09–6.98)	5.8 (0.62–54.35)	0.07 (0.01–0.72)	0.77 (0.09–6.69)
Late (>40 weeks) ($n = 181$)	0.94 (0.51–1.74)	1.05 (0.66–1.66)	1.96 (0.87–4.43)	1.19 (0.33–4.31)	1.17 (0.66–2.07)	0.44 (0.13–1.53)	1.92 (0.32–11.66)	1.06 (0.61–1.87)
Abnormal placenta ($n = 9$)	NC	0.49 (0.10–2.49)	3.21 (0.62–16.69)	NC	0.57 (0.07–4.69)	NC	NC	0.54 (0.07–4.50)

The significant associations are bolded

Regarding to allele G*01:01:03, which Ferguson et al. found to increase the risk persistent genital HPV infections (OR = 2.07) [12], we also observed this allele to increase the risk for multiple-type oral infections (OR = 3.32) but not for genital infections (Table 1).

There seems to be some parallel trends recorded in both genital and oral infections, but interestingly, in the present study we were unsuccessful to show any association

between HLA-G polymorphism and genital HPV infections. The potential reasons might be that the previous studies have been somewhat larger ($N = 539$ – 636) [12, 13, 23], and importantly, focused on populations of different origin (Hispanics, Inuites) [23, 30], thus representing a larger scale of HLA-G polymorphism available as potential predictors of genital HPV infection outcomes, which might explain the divergent results [12, 13, 23, 30].

Table 4 Association between HLA-G genotypes and risk factors for HPV infection recorded by the baseline questionnaire

Risk factors	HLA-G genotype OR (95% CI)					
	*010101: 010101	*010101:010102	*010101:010103	*010101: 010401	*010102: 010102	*010102:010401
Miscarriages (≥ 1) (n = 39)	0.81 (0.37–1.75)	1.13 (0.53–2.42)	1.39 (0.38–5.10)	0.50 (0.15–1.73)	2.18 (0.42–11.24)	0.70 (0.09–5.67)
Infertility (n = 24)	1.09 (0.45–2.66)	1.13 (0.45–2.85)	0.70 (0.09–5.51)	0.24 (0.03–1.84)	1.54 (0.18–13.07)	5.06 (1.22–21.02)
Infertility treatments (n = 15)	0.54 (0.15–1.95)	1.36 (0.45–4.13)	1.17 (0.14–9.52)	0.42 (0.05–3.28)	NC	9.07 (2.08–39.50)
Sexually transmitted diseases (n = 63)	1.40 (0.78–2.51)	0.68 (0.35–1.33)	1.08 (0.34–3.37)	0.59 (0.24–1.48)	0.44 (0.05–3.52)	0.89 (0.19–4.22)
Warts						
Genital (n = 80)	0.62 (0.34–1.12)	1.18 (0.66–2.11)	0.53 (0.15–1.89)	1.88 (0.94–3.77)	0.85 (0.17–4.29)	0.72 (0.15–3.55)
Oral (n = 8)	NC	4.85 (1.13–20.85)	6.00 (1.11–32.46)	NC	NC	NC
Skin (n = 166)	0.96 (0.59–1.56)	1.29 (0.77–2.14)	1.98 (0.73–5.35)	0.69 (0.37–1.32)	0.87 (0.25–3.08)	0.18 (0.04–0.87)
Allergies (n = 126)	1.07 (0.64–1.77)	0.88 (0.52–1.50)	0.95 (0.34–2.63)	1.13 (0.58–2.20)	2.08 (0.49–8.89)	2.52 (0.62–10.29)
Atopia (n = 43)	0.62 (0.29–1.32)	1.38 (0.68–2.79)	0.34 (0.04–2.63)	0.59 (0.20–1.74)	1.80 (0.35–9.25)	2.78 (0.67–11.55)
Vulvovaginitis (n = 48)	1.31 (0.31–5.60)	0.39 (0.05–3.20)	NC	NC	NC	NC
Menarche						
Late (> 14 years) (n = 21)	0.96 (0.36–2.59)	0.67 (0.22–2.08)	3.12 (0.81–12.03)	2.37 (0.44–12.66)	NC	1.37 (0.16–11.38)
Early (< 11 years) (n = 7)	1.71 (0.37–7.83)	0.45 (0.05–3.82)	NC	1.01 (0.28–3.64)	NC	NC
Start of labour						
Own contractions (n = 145)	1.11 (0.66–1.87)	0.96 (0.57–1.65)	0.65 (0.24–1.75)	1.12 (0.57–2.18)	0.75 (0.20–2.86)	0.75 (0.20–2.86)
Rupture of the membranes (n = 52)	1.43 (0.75–2.74)	1.31 (0.67–2.55)	0.26 (0.03–2.03)	0.43 (0.15–1.28)	1.28 (0.26–6.37)	1.28 (0.26–6.37)
Induction (n = 91)	0.87 (0.50–1.53)	0.79 (0.44–1.41)	1.12 (0.40–3.13)	1.74 (0.89–3.44)	0.57 (0.12–2.81)	0.72 (0.81–4.07)
Labour weeks						
Early (< 37 weeks) (n = 8)	1.08 (0.19–5.99)	2.75 (0.54–13.90)	NC	NC	NC	NC
Late (> 40 weeks) (n = 181)	0.82 (0.51–1.33)	0.97 (0.59–1.62)	2.32 (0.81–6.61)	1.30 (0.68–2.50)	0.51 (0.14–1.86)	0.95 (0.28–3.17)
Abnormal placenta (n = 9)	1.30 (0.30–5.56)	0.89 (0.18–4.51)	5.51 (1.03–29.37)	0.85 (0.10–7.06)	NC	NC

The significant associations are bolded

Only a few studies have assessed the associations between HLA-G polymorphism and female reproductive health [31, 32]. HLA-G seems to play a major role as a suppressor of the immune response at the maternal-fetal interface as well as in placental angiogenesis [33]. Craenmehr et al. reported HLA-G overexpression in the full-term placenta of the women with a history of recurrent miscarriages (OR = 6.67) [31]. In another study, HLA-G gene alleles *0106, *010106, *010106 and *0105 N were significantly higher in patients with embryonic implantation failure on infertility treatments [32]. In the present study, we could not confirm these results on HLA-G alleles, but we showed an association with HLA-G G*01:01:02/01:04:01 genotype and risk of both infertility and undergoing treatments for infertility, OR = 5.06 and OR = 9.07, respectively (Table 4). In addition, genotype

G*01:01:01/01:01:03 was significantly associated with an abnormal placenta (OR = 5.51).

This study has some potential limitations. The FFHPV cohort consists only of Caucasian Finnish women, and accordingly, the generalization to other populations is limited because Finland has its limited gene pool [34]. Cohort size of women was quite small, only 306 women, thus impeding the power to evaluate any associations of the rarest HLA-G genotypes. Regarding our reproductive risk factors all women in our cohort were pregnant at study baseline and the cohort is not a representative series of infertility clinic patients. The data on their reproductive health are based on the women's self-reported statements. The main strength of this study is the vast database from a long-term prospective study that included study subjects with similar lifestyle and biological background, followed-up a for a long period

of time with detailed HPV status of both the genital and oral sites.

Conclusions

In conclusion, we identified six clinically significant HLA-G genotypes in women which affecting, however, only the HPV status and infection outcomes in oral mucosa, but not in genital tract. In addition, HLA-G genotype *01:01:02/01:04:01 showed to be associated with the reported history of infertility. Further studies on HLA-G polymorphism are warranted to confirm their impact as predictors of the natural history of HPV infections at different anatomic sites.

Acknowledgements

Not applicable.

Authors' contributions

AJ, MR, MCF, KS, SG, SS and KL have been involved in the design of the study, analyses of the results and drafting the content and structure of the manuscript and have approved the final version.

Funding

This study has been supported by the Academy of Finland (#116438/2006, #130204/2008), Finnish Cancer Foundation, Sohlberg Foundation, Finnish Dental Society, Finnish Medical Foundation, Sigrid Juselius Foundation, Government Special Foundation (EVO) to Turku University Hospital, Emil Aaltonen Foundation, Sexually Transmitted Disease Association and Finnish Cultural Foundation. The funders were not involved in the design of the study and have no ownership over the management of the study, the data, or the rights to publish.

Availability of data and materials

Data is available upon reasonable request from the corresponding author.

Declarations

Ethics approval and consent to participate

The Research Ethics Committee of Turku University Hospital (#3/1998 and #2/2006) has approved the study protocol and its amendments. All the participants gave their written consent for the cohort study.

Consent for publication

Not applicable.

Competing interests

Nothing to declare.

Author details

¹Turku University Hospital, University of Turku, Turku, Finland. ²Department of Obstetrics and Gynecology, Kymenlaakso Central Hospital, Kotkantie 41, 48210 Kotka, Finland. ³Centre de Recherche du CHUM, Montreal, Canada. ⁴Département de Microbiologie, Infectiologie et Immunologie, de l'Université de Montréal, Montreal, Canada. ⁵Department of Clinical Research, Biohit Oyj, Helsinki, Finland. ⁶Department of Oral Pathology and Radiology, University of Turku, Turku, Finland. ⁷Department of Pathology, Turku University Hospital, University of Turku, Turku, Finland. ⁸Department of Obstetrics and Gynecology, Tampere University and Tampere University Hospital, Tampere, Finland.

Received: 8 February 2021 Accepted: 15 April 2021

Published online: 04 May 2021

References

1. Syrjänen K, Hakama M, Saarikoski S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a

- nonselected Finnish female population. *Sex Transm Dis*. 1990;17(1):15–9. <https://doi.org/10.1097/00007435-199017010-00004>.
2. Tam S, Fu S, Xu L, Krause KJ, Lairson DR, Miao H, et al. The epidemiology of oral human papillomavirus infection in healthy populations: a systematic review and meta-analysis. *Oral Oncol*. 2018;82:91–9. <https://doi.org/10.1016/j.oraloncology.2018.04.005>.
3. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. *Hum Vaccin Immunother*. 2019;15(1):146–55. <https://doi.org/10.1080/21645515.2018.1512453>.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol*. 1999;189(1):12–9. [https://doi.org/10.1002/\(SICI\)1096-9896\(199909\)189:1<12::AID-PATH431>3.0.CO;2-F](https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F).
5. de Sanjose S, Serrano B, Tous S, et al. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPV6/11/16/18/31/33/45/52 and 58. *JNCI Cancer Spectr*. 2019;2:pkv045.
6. Tan G, Duan M, Li Y, et al. Distribution of HPV 16 E6 gene variants in screening women and its associations with cervical lesions progression. *Virus Res*. 2019;273:197740. <https://doi.org/10.1016/j.virusres.2019.197740>.
7. Duan R, Qiao Y, Clifford G, Zhao F. Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. *Cancer Med*. 2020;9(1):374–84. <https://doi.org/10.1002/cam4.2697>.
8. Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. *Hum Vaccin Immunother*. 2019;15(7–8):1920–8. <https://doi.org/10.1080/21645515.2019.1600985>.
9. Kreimer AR, Chaturvedi AK, Alemany L, Anantharaman D, Bray F, Carrington M, et al. Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. *Oral Oncol*. 2020;108:104736. <https://doi.org/10.1016/j.oraloncology.2020.104736>.
10. Frazer IH. Immunology of papillomavirus infection. *Curr Opin Immunol*. 1996;8(4):484–91. [https://doi.org/10.1016/S0952-7915\(96\)80035-5](https://doi.org/10.1016/S0952-7915(96)80035-5).
11. Xu HH, Yan WH, Lin A. The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis. *Front Immunol*. 2020;11:1349.
12. Ferguson R, Ramanakumar AV, Richardson H, Tellier PP, Coutlée F, Franco EL, et al. Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. *Hum Immunol*. 2011;72(4):337–41. <https://doi.org/10.1016/j.humimm.2011.01.010>.
13. Ferguson R, Ramanakumar AV, Koushik A, Coutlée F, Franco E, Roger M, et al. Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix. *Int J Cancer*. 2012;131(3):E312–9. <https://doi.org/10.1002/ijc.27356>.
14. Li XJ, Zhang X, Lin A, Ruan YY, Yan WH. Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. *Hum Immunol*. 2012;73(9):946–9. <https://doi.org/10.1016/j.humimm.2012.07.041>.
15. Dong DD, Yang H, Li K, et al. Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response. *Reprod Sci*. 2010;17(8):718–23. <https://doi.org/10.1177/1933719110369183>.
16. Delves PJ, Roitt IM. The immune system. Second of two parts. *N Engl J Med*. 2000;343:108–117, 2. DOI: <https://doi.org/10.1056/NEJM200007133430207>.
17. Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V. Recent advances in our understanding of HLA-G biology: lessons from a wide Spectrum of human diseases. *J Immunol Res*. 2016;2016:4326495.
18. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. *Nature*. 1999;401(6756):921–3. <https://doi.org/10.1038/44853>.
19. Sheu J, Shih I. HLA-G and immune evasion in cancer cells. *J Formos Med Assoc*. 2010;109(4):248–57. [https://doi.org/10.1016/S0929-6646\(10\)60050-2](https://doi.org/10.1016/S0929-6646(10)60050-2).
20. Ferreira LMR, Meissner TB, Tilburgs T, Strominger JL. HLA-G: at the Interface of maternal-fetal tolerance. *Trends Immunol*. 2017;38(4):272–86. <https://doi.org/10.1016/j.it.2017.01.009>.
21. Zheng N, Wang CX, Zhang X, du LT, Zhang J, Kan SF, et al. Up-regulation of HLA-G expression in cervical premalignant and malignant lesions. *Tissue Antigens*. 2011;77(3):218–24. <https://doi.org/10.1111/j.1399-0039.2010.01607.x>.
22. Yoon BS, Kim YT, Kim JW, Kim SH, Kim JH, Kim SW. Expression of human leukocyte antigen-G and its correlation with interleukin-10 expression in cervical carcinoma. *Int J Gynaecol Obstet*. 2007;98(1):48–53. <https://doi.org/10.1016/j.jigo.2007.03.041>.

23. Metcalfe S, Roger M, Faucher MC, Coutlee F, Franco EL, Brassard P. The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec. *Hum Immunol.* 2013;74(12):1610–5. <https://doi.org/10.1016/j.humimm.2013.08.279>.
24. Simoes RT, Goncalves MA, Castelli EC, et al. HLA-G polymorphisms in women with squamous intraepithelial lesions harboring human papillomavirus. *Mod Pathol.* 2009;22(8):1075–82. <https://doi.org/10.1038/modpathol.2009.67>.
25. Rintala M, Grenman S, Puranen M, Syrjanen S. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV family study. *J Clin Virol.* 2006;35(1):89–94. <https://doi.org/10.1016/j.jcv.2005.05.012>.
26. Louvanto K, Rintala MA, Syrjanen KJ, Grenman SE, Syrjanen SM. Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish family HPV study. *J Infect Dis.* 2010;202(3):436–44. <https://doi.org/10.1086/653826>.
27. Snijders PJ, van den Brule AJ, Schrijnemakers HF, Snow G, Meijer CJ, Walboomers JM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. *J Gen Virol.* 1990;71(Pt 1):173–81. <https://doi.org/10.1099/0022-1317-71-1-173>.
28. Rautava J, Syrjanen S. Biology of human papillomavirus infections in head and neck carcinogenesis. *Head Neck Pathol.* 2012;6(Suppl 1):S3–15.
29. Louvanto K, Roger M, Faucher MC, Syrjanen K, Grenman S, Syrjanen S. HLA-G and vertical mother-to-child transmission of human papillomavirus infection. *Hum Immunol.* 2018;79(6):471–6. <https://doi.org/10.1016/j.humimm.2018.03.002>.
30. Alves BM, Prellwitz IM, Siqueira JD, Meyrelles AR, Bergmann A, Seuánez HN, et al. The effect of human leukocyte antigen G alleles on human papillomavirus infection and persistence in a cohort of HIV-positive pregnant women from Brazil. *Infect Genet Evol.* 2015;34:339–43. <https://doi.org/10.1016/j.meegid.2015.06.027>.
31. Craenmehr MHC, Nederlof I, Cao M, et al. Increased HLA-G Expression in Term Placenta of Women with a History of Recurrent Miscarriage Despite Their Genetic Predisposition to Decreased HLA-G Levels. *Int J Mol Sci.* 2019;20. <https://doi.org/10.3390/ijms20030625>.
32. Kuroshli Z, Gourabi H, Bazrgar M, Sanati M, Zamani EM. The relationship between HLA-G gene polymorphisms and repeated implantation failure in infertile couples undergoing assisted reproductive technique. *Iran J Allergy Asthma Immunol.* 2015;14:535–42.
33. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. *Science.* 1990;248(4952):220–3. <https://doi.org/10.1126/science.2326636>.
34. Kaariainen H, Muilu J, Perola M, Kristiansson K. Genetics in an isolated population like Finland: a different basis for genomic medicine? *J Community Genet.* 2017;8(4):319–26. <https://doi.org/10.1007/s12687-017-0318-4>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions